BioSpace News Archive

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that a virtual meeting of the U.S. Food and Drug Administration’s Psychopharmacologic Drugs Advisory Committee to review the resubmitted supplemental New Drug Application (sNDA) for pimavanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP) has been scheduled for June 17, 2022.

Selecta Biosciences, Inc. announced six upcoming presentations, including three joint presentations with our partner AskBio, at the 25th Annual Meeting of the American Society of Gene & Cell Therapy, to be held virtually and in-person from May 16-19, 2022 in Washington, D.C.

Century Therapeutics announced that preclinical data on MAD7, a novel CRISPR nuclease used to enable the genetic engineering of iPSC-derived NK and T cell product candidates, will be presented in a poster at the American Society of Gene and Cell Therapy 25th Annual Meeting, on May 16-19, 2022 in Washington, D.C.

Cabaletta Bio, Inc. announced that data from its two lead programs, DSG3-CAART and MuSK-CAART, will be presented at multiple upcoming scientific meetings in May 2022.

Arbor Biotechnologies announced upcoming preclinical data presentations at the 25th Annual Meeting of the American Society of Gene & Cell Therapy being held May 16-19, 2022, in Washington, D.C.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, announced today that it will present new preclinical data on PH-894 for use in adoptive cell therapy (ACT) at the American Society for Gene and Cell Therapy (ASGCT) 25th Annual Meeting.

CERo Therapeutics, Inc., today announced new preclinical data to be presented at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) demonstrating significant anti-tumor effects of chimeric engulfment receptor (CER) T cells when combined with small molecule therapies in both hematologic and solid tumor models.

uniQure N.V. announced that six data presentations, including one oral presentation, will be delivered at the American Society of Gene and Cell Therapy Hybrid Congress 2022 Annual Meeting being held May 16-19 in Washington, D.C.

Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the first quarter of 2022 after the market closes on Monday, May 9, 2022.

Freeline Therapeutics Holdings plc announced the upcoming presentation of five posters at the 25th Annual Meeting of the American Society of Gene and Cell Therapy that will take place May 16-19, 2022 in Washington, D.C.